In neurodegenerative diseases, NNMT reduces the catalytic ability of LCMT-1 by decreasing the concentration of SAM, leading to a decrease in the activity of LET-92/PP2A (Schmeisser and Parker, 2018). Here, PTPA is linked to neurodegenerative disease.